ERAS News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

ER

Mkt Cap

$4.69B

Volume

6.33M

Next Earnings

November 11th

Loading chart

ER

ERASErasca, Inc. Common Stock

ERAS

Pay with—

Available Balance0.00

ER

Mkt Cap

$5.20B

Volume

6.33M

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar Law Office is Investigating Claims on Your BehalfGrabar Law Office is investigating securities fraud and fiduciary duty breach claims against four companies: Aardvark Therapeutics for allegedly misrepresenting the safety profile of its drug candidate ARD-101 before a clinical hold was placed; Coastal Financial Corporation for failing to disclose deterioration in its CCBX partner loan portfolio and credit losses; Erasca, Inc. for making misleading statements about its ERAS-0015 therapy and improper comparisons to competitors; and New Era Energy & Digital for overstating progress on its data center project and allegedly engaging in fraudulent oil-and-gas schemes.GlobeNewswire Inc. · Oct 8, 2026

EMBECTA CORP. (NASDAQ: EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary DutyLaw firm Bernstein Liebhard announced an investigation into potential breaches of fiduciary duty by directors and officers of Embecta Corp. The firm is seeking to determine whether company leadership fulfilled its obligations to shareholders. Current shareholders who purchased shares before November 25, 2025 are encouraged to contact the firm regarding their legal rights.GlobeNewswire Inc. · Sep 22, 2026

ROSEN, LEADING INVESTOR COUNSEL, Encourages Datavault AI Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DVLTRosen Law Firm has filed class action lawsuits against Datavault AI Inc. (DVLT), Planet Fitness, Inc. (PLNT), and Erasca, Inc. (ERAS) on behalf of investors who purchased securities during specified periods. The lawsuits allege materially false and misleading statements, including overstated partnerships, inflated trading volumes, and undisclosed connections to convicted felons. Investors have until October 5, 2026 to move the court to serve as lead plaintiff.GlobeNewswire Inc. · Aug 8, 2026

ERASCA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important August 10 Deadline in Securities Class Action – ERASA securities class action lawsuit has been filed against Erasca, Inc. and its executives for allegedly making false and misleading statements about its lead oncology drug candidate ERAS-0015. The company is accused of improperly comparing its drug to a competitor's candidate and failing to disclose patent and trade secret disputes. Investors who purchased Erasca stock between January 14, 2025 and April 26, 2026 must act by August 10, 2026 to serve as lead plaintiff.GlobeNewswire Inc. · Aug 8, 2026

ERASCA LEAD PLAINTIFF DEADLINE AUGUST 10th: Bragar Eagel & Squire, P.C. Reminds Erasca, Inc. (ERAS) Investors with Large Losses to Contact the Firm Regarding their RightsA class action lawsuit has been filed against Erasca, Inc. alleging that the company made false and misleading statements regarding its ERAS-0015 drug candidate. The lawsuit claims the preclinical data was based on improper comparisons and lacked reasonable basis. Following a patent infringement allegation from Revolution Medicines disclosed on April 28, 2026, Erasca's stock price declined approximately 48% from $19.15 to $9.90 per share. Investors have until August 10, 2026 to apply as lead plaintiff.GlobeNewswire Inc. · Aug 7, 2026

ERAS 3-DAY DEADLINE ALERT: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit– Hagens BermanHagens Berman is investigating securities fraud claims against Erasca, Inc. for allegedly misleading investors about its lead oncology drug ERAS-0015's competitive advantages, safety profile, and intellectual property protections. The company faces patent infringement allegations from Revolution Medicines and reported a patient death in clinical trials, triggering a $2.8 billion market capitalization loss. Investors with substantial losses can serve as lead plaintiffs with an August 10, 2026 deadline.GlobeNewswire Inc. · Aug 7, 2026

Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Insulet Corporation (NASDAQ: PODD); Power Solutions International, Inc. (NASDAQ: PSIX); and PROCEPT BioRobotics Corporation (NASDAQ: PRCT): Grabar Law Office is Investigating Claims on Your BehalfGrabar Law Office has filed federal securities fraud class action investigations against four companies: Erasca for misleading statements about its ERAS-0015 drug candidate and undisclosed patent risks; Insulet for defective manufacturing controls leading to voluntary product corrections; Power Solutions for overstating sales demand and understating manufacturing costs; and PROCEPT BioRobotics for using undisclosed discount programs that artificially inflated sales and created excess inventory. Shareholders who purchased shares during specified periods are eligible to seek damages and corporate reforms.GlobeNewswire Inc. · Aug 7, 2026

Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application DeadlineHagens Berman is investigating securities fraud claims against Erasca, Inc. for allegedly misleading investors about its lead oncology drug ERAS-0015's competitive advantages, safety profile, and intellectual property protections. The company faces patent infringement allegations from Revolution Medicines and reported a patient death in clinical trials. These disclosures in late April 2026 triggered a sharp stock decline, erasing over $2.8 billion in market capitalization. The lead plaintiff deadline is August 10, 2026.GlobeNewswire Inc. · Aug 6, 2026

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Pentair plc Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - PNRRosen Law Firm has filed class action lawsuits against Pentair plc, First Solar, Inc., and Erasca, Inc. on behalf of investors who suffered losses. The Pentair lawsuit alleges the company made false statements about its business while concealing significant inventory destocking in the Pool channel that adversely affected sales and operating income. Investors with losses exceeding $100,000 are encouraged to join the class actions before upcoming deadlines.GlobeNewswire Inc. · Aug 5, 2026

DEADLINE ALERT for ERAS, VIA, EMBC, Z: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class ActionsClass action lawsuits have been filed against four publicly-traded companies alleging securities fraud. Erasca faces allegations regarding misleading preclinical data comparisons; Via Transportation failed to disclose declining ARR and regulatory issues; Embecta misrepresented guidance and segment weakness; and Zillow mischaracterized its Redfin agreement and downplayed antitrust risks. Investors have until mid-August 2026 to file lead plaintiff motions.GlobeNewswire Inc. · Aug 5, 2026

to start trading

ER

ERASErasca, Inc. Common Stock

ERAS

Pay with—

Available Balance0.00

Your PositionYou don't own any ERAS yet.

Related Tickers

Earnings